Celldex Therapeutics, Inc. Stock, NASDAQ:CLDX
53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ 08827
United States of America
Number of Employees: 133
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers. In addition, the company focuses on the discovery and development of antibody-based drugs targeting receptor tyrosine kinases, such as CDX-0158, a humanized monoclonal antibody currently in a Phase 1 dose escalation study in refractory gastrointestinal stromal tumors and other KIT positive tumors; and CDX-3379, a human monoclonal antibody, which has completed a Phase 1b study in patients with solid tumors. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. The company is headquartered in Hampton, New Jersey.